Focused On-demand Library for Terminal nucleotidyltransferase 5C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5VWP2

UPID:

TET5C_HUMAN

Alternative names:

Non-canonical poly(A) polymerase FAM46C

Alternative UPACC:

Q5VWP2; A3KMG2; Q8NE25; Q9NXK0

Background:

Terminal nucleotidyltransferase 5C, also known as Non-canonical poly(A) polymerase FAM46C, plays a crucial role in mRNA stability and gene expression by catalyzing the transfer of adenosine from ATP to mRNA poly(A) tails. This process not only enhances mRNA stability but also promotes gene expression, with a specific focus on mRNAs encoding endoplasmic reticulum-targeted proteins. Additionally, it has been observed to facilitate the replication of certain viruses, including the yellow fever virus, in response to type I interferon.

Therapeutic significance:

Understanding the role of Terminal nucleotidyltransferase 5C could open doors to potential therapeutic strategies, especially in the context of viral infections and the regulation of gene expression related to endoplasmic reticulum-targeted proteins.